New molecular entities.
- Published in:
- Formulary, 2006, v. 41, n. 11, p. 555
- Publication type:
- Article
Works matching DE "SEPRACOR Inc."
Results: 9
1
2
New molecular entities.
- Published in:
- Formulary, 2005, v. 40, n. 2, p. 39
- Publication type:
- Article
3
Effects of a Short Course of Eszopiclone on Continuous Positive Airway Pressure Adherence.
- Published in:
- Annals of Internal Medicine, 2009, v. 151, n. 10, p. 696, doi. 10.7326/0003-4819-151-10-200911170-00006
- By:
- Publication type:
- Article
4
SEPRACOR PROVIDES UPDATE ON CLINICAL TRIALS FOR SEP-225289 AND LUNESTA PEDIATRICS.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 7, p. 51
- Publication type:
- Article
5
SEPRACOR REPORTS PRELIMINARY PHASE II STUDY RESULTS FOR SEP-225441 FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 3, p. 13
- Publication type:
- Article
6
Business digest.
- Published in:
- Chemistry & Industry, 2009, n. 18, p. 13
- Publication type:
- Article
7
Maturing biotechs turn to pharma's markets.
- Published in:
- Nature Biotechnology, 2005, v. 23, n. 3, p. 269, doi. 10.1038/nbt0305-269
- By:
- Publication type:
- Article
8
Redesigner drugs.
- Published in:
- Nature Biotechnology, 2004, v. 22, n. 8, p. 953, doi. 10.1038/nbt0804-953
- By:
- Publication type:
- Article
9
S-Oxybutynin.
- Published in:
- Drugs in R&D, 2002, v. 3, n. 2, p. 84, doi. 10.2165/00126839-200203020-00003
- Publication type:
- Article